Pluristem Therapeutics Inc., of Haifa, Israel, said, due to increased demand, it entered an amended and restated underwriting agreement, with H.C. Wainwright & Co. LLC acting as the sole book-running manager, to increase the size of the previously announced bought deal to $15 million. The underwriter agreed to buy about 12.2 million shares priced at $1.225 each, with warrants to purchase up to about 7.3 million shares. Pluristem also granted the underwriter a 30-day option to purchase up to an additional 1.8 million shares and/or with warrants to purchase 1.1 million shares, for additional aggregate proceeds of up to about $2.25 million.